Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539

Amantadine (1-amino-adamantane) is a versatile antiviral compound which has been licensed for decades against influenza viruses. During the Corona pandemic, its effect to inhibit SARS-CoV-2 in vitro has been investigated. However, an in vivo oral inapplicability was concluded due to ID(50) doses exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bode, Liv, Dietrich, Detlef E., Spannhuth, Carsten W., Ludwig, Hanns
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953669/
https://www.ncbi.nlm.nih.gov/pubmed/35336901
http://dx.doi.org/10.3390/v14030494
_version_ 1784675908054941696
author Bode, Liv
Dietrich, Detlef E.
Spannhuth, Carsten W.
Ludwig, Hanns
author_facet Bode, Liv
Dietrich, Detlef E.
Spannhuth, Carsten W.
Ludwig, Hanns
author_sort Bode, Liv
collection PubMed
description Amantadine (1-amino-adamantane) is a versatile antiviral compound which has been licensed for decades against influenza viruses. During the Corona pandemic, its effect to inhibit SARS-CoV-2 in vitro has been investigated. However, an in vivo oral inapplicability was concluded due to ID(50) doses exceeding eight times the estimated maximum tolerable plasma levels reached by 600 mg orally daily. In contrast, amantadine has been shown to be extraordinarily efficient against human neurotropic Borna disease virus (BoDV-1), presenting with both anti-depressive and anti-viral efficacy against a placebo, achieved by a well-tolerated low oral daily dose of 200 mg amantadine.
format Online
Article
Text
id pubmed-8953669
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89536692022-03-26 Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539 Bode, Liv Dietrich, Detlef E. Spannhuth, Carsten W. Ludwig, Hanns Viruses Comment Amantadine (1-amino-adamantane) is a versatile antiviral compound which has been licensed for decades against influenza viruses. During the Corona pandemic, its effect to inhibit SARS-CoV-2 in vitro has been investigated. However, an in vivo oral inapplicability was concluded due to ID(50) doses exceeding eight times the estimated maximum tolerable plasma levels reached by 600 mg orally daily. In contrast, amantadine has been shown to be extraordinarily efficient against human neurotropic Borna disease virus (BoDV-1), presenting with both anti-depressive and anti-viral efficacy against a placebo, achieved by a well-tolerated low oral daily dose of 200 mg amantadine. MDPI 2022-02-28 /pmc/articles/PMC8953669/ /pubmed/35336901 http://dx.doi.org/10.3390/v14030494 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Bode, Liv
Dietrich, Detlef E.
Spannhuth, Carsten W.
Ludwig, Hanns
Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title_full Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title_fullStr Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title_full_unstemmed Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title_short Prominent Efficacy of Amantadine against Human Borna Disease Virus Infection In Vitro and In Vivo. Comment on Fink et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539
title_sort prominent efficacy of amantadine against human borna disease virus infection in vitro and in vivo. comment on fink et al. amantadine inhibits sars-cov-2 in vitro. viruses 2021, 13, 539
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953669/
https://www.ncbi.nlm.nih.gov/pubmed/35336901
http://dx.doi.org/10.3390/v14030494
work_keys_str_mv AT bodeliv prominentefficacyofamantadineagainsthumanbornadiseasevirusinfectioninvitroandinvivocommentonfinketalamantadineinhibitssarscov2invitroviruses202113539
AT dietrichdetlefe prominentefficacyofamantadineagainsthumanbornadiseasevirusinfectioninvitroandinvivocommentonfinketalamantadineinhibitssarscov2invitroviruses202113539
AT spannhuthcarstenw prominentefficacyofamantadineagainsthumanbornadiseasevirusinfectioninvitroandinvivocommentonfinketalamantadineinhibitssarscov2invitroviruses202113539
AT ludwighanns prominentefficacyofamantadineagainsthumanbornadiseasevirusinfectioninvitroandinvivocommentonfinketalamantadineinhibitssarscov2invitroviruses202113539

Ejemplares similares